2013
DOI: 10.1186/1471-2105-14-145
|View full text |Cite
|
Sign up to set email alerts
|

Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform

Abstract: BackgroundImmunoassays that employ multiplexed bead arrays produce high information content per sample. Such assays are now frequently used to evaluate humoral responses in clinical trials. Integrated software is needed for the analysis, quality control, and secure sharing of the high volume of data produced by such multiplexed assays. Software that facilitates data exchange and provides flexibility to perform customized analyses (including multiple curve fits and visualizations of assay performance over time)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 52 publications
0
6
0
Order By: Relevance
“…Accordingly, generating a robust set of quality controls for clinical diagnostics applicable to different assays/platforms presents a significant technical challenge and currently quantitative comparison of samples between different platforms is markedly inconsistent. Currently, ascertaining quality control over several assay cycles laboriously involves calculating representative metrics for each standard curve per cycle, plotting the attained metrics and expected ranges on Levey–Jennings charts to define outliers, excluding data from analysis based on quality metrics and identifying trends that require further investigation . A lack of robust multivariate quality control algorithms and data rejection criteria for multiplexed immunoassays is also problematic.…”
Section: Validation Of Multiplex Immunoassaysmentioning
confidence: 99%
“…Accordingly, generating a robust set of quality controls for clinical diagnostics applicable to different assays/platforms presents a significant technical challenge and currently quantitative comparison of samples between different platforms is markedly inconsistent. Currently, ascertaining quality control over several assay cycles laboriously involves calculating representative metrics for each standard curve per cycle, plotting the attained metrics and expected ranges on Levey–Jennings charts to define outliers, excluding data from analysis based on quality metrics and identifying trends that require further investigation . A lack of robust multivariate quality control algorithms and data rejection criteria for multiplexed immunoassays is also problematic.…”
Section: Validation Of Multiplex Immunoassaysmentioning
confidence: 99%
“…2). BLIS is a customized instance of the open-source LabKey [6][7][8][9][10], an application developed to integrate, analyze, and share biomedical research data, including flow cytometry, proteomics, Luminex, ELISpot, ELISA, Nab, rt-PCR, other plate-based assay data, as well as specimen inventory and clinical subject data (Fig. 2).…”
Section: Resultsmentioning
confidence: 99%
“…To effectively use data science techniques to resolve these translational questions requires innovation in the organization and management of these data. For over a decade the informatics team of the University of Rochester Clinical and Translational Science Institute's Research Data Integration and Analytics group has been developing comprehensive data management workflows for laboratory assays, specimen inventories, and study-specific data using the open-source LabKey platform [6][7][8][9][10]. Early funding for this effort came from several NIAID grants that recognized the need to develop a system to manage and integrate high-throughput genomics and related data from human subjects.…”
Section: Introductionmentioning
confidence: 99%
“…Quality control (QC) acceptance criteria for Triplex PK assay include but are not limited to: 1) FI-Bkgd readout must have a percentage of coefficient of variation (%CV) between replicates < 20% for each dilution in the titration series and < 15% for a sample that is assayed at a single dilution when fluorescence- background (FI-Bkgd)>100, 2) Three out of five spiked controls must have a recovery between 70 -130% of their input concentration, and 3) the positive control antibody titer, defined as the half maximal effective concentration (EC50) from a five parameter logistic curve fit (5PL) and the highest FI-Bkgd in the positive control standard curve must be within three standard deviations of the historical mean as tracked with Levey-Jennings charts [Portal, Labkey, Seattle, WA ( 25 )]. Guide sets for Levey-Jennings charts that enable tracking of positive controls to historical data were established from >10 standardized assays.…”
Section: Methodsmentioning
confidence: 99%